🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Keros Therapeutics, Inc. KROS R2K

Healthcare · Biotechnology · United States
https://www.kerostx.com

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

READ MORE ›
$11.25
-20.49% 1Y

Market & Price

Market Cap
$222.66M
Current Price
$11.25
High / Low (52W)
$21.84 / $9.91
Beta
0.95

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$14.47
Price to Book
0.78
P/S
6.71
EV/EBITDA
0.40
Dividend Yield
-

Profitability & Returns

ROCE
21.27%
ROE
-16.79%
ROA
-12.23%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$-1.21
EPS (TTM)
$-2.53

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
22.17
Current Ratio
22.61
Debt
$16.31M
Total Assets
$338.02M
Current Assets
$315.43M
Working Capital
$295.02M

Ownership

Promoter Holding
3.65%
Chg in Prom Hold
-
FII / Inst Holding
96.04%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$-42.53M
Total Revenue (TTM)
$33.18M
EBITDA
$-105.78M
Free Cash Flow
$-37.69M
Operating Cash Flow
$-57.20M
Shares Outstanding
19.79M
Gross Margin
-
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
61.04%
Revenue (YoY)
-99.80%
Earnings (YoY)
-

PROS

  • Healthy ROCE of 21.3%.
  • Profit CAGR of 61.0% over 5 years.

CONS

  • Trading 48.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KROS Keros Therapeutics, Inc. R2K 11.25 - $222.66M - 21.27% -16.79% - 61.04%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2.50M2.50M2.50M000-100.00K0-00008.00K83.00K37.00K388.00K211.25M18.17M14.26M385.00K367.00K
Cost of Revenue -----------------------
Gross Profit -----------------------
Operating Expenses ------------------59.21M57.98M29.65M29.66M26.24M
Operating Income -2.86M-2.65M-2.33M-10.50M-10.91M-11.95M-15.77M-15.54M-20.20M-24.13M-30.73M-27.98M-38.87M-41.34M-43.28M-48.48M-50.44M-58.66M152.04M-39.82M-15.38M-29.27M-25.88M
EBITDA ------------------152.38M-39.45M-14.99M-28.87M-25.47M
Interest Expense -----------------------
Pretax Income ------------------158.49M-32.92M-8.70M-24.98M-23.71M
Tax Provision ------------------10.04M-2.22M-1.42M-1.51M0
Net Income -3.18M-2.85M-3.55M-11.89M-10.76M-12.04M-15.88M-15.62M-20.30M-24.19M-27.27M-23.51M-35.80M-37.51M-39.44M-43.11M-45.26M-52.96M148.45M-30.70M-7.28M-23.46M-23.71M
Diluted EPS -----0.62-0.60-0.68-0.67-0.87-1.01-1.13-0.92-1.26-1.27-1.33-1.21-1.25-1.413.62-0.76-0.18-0.86-1.21
R&D Expense 4.87M4.50M3.85M8.53M7.26M8.39M11.49M9.98M14.83M18.08M23.28M21.04M31.09M32.53M34.14M38.26M40.52M49.23M48.71M43.50M19.52M-16.10M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 10.00M0-0151.00K3.55M244.06M
Cost of Revenue -------
Gross Profit -------
Operating Expenses ---107.71M167.69M213.15M176.49M
Operating Income -10.56M-46.66M--107.71M-167.54M-209.59M67.57M
EBITDA ----104.00M-152.18M-208.37M69.08M
Interest Expense --4.00K1.00K00-
Pretax Income ----104.68M-152.99M-187.05M91.90M
Tax Provision ---00300.00K4.88M
Net Income -12.34M-45.36M--104.68M-152.99M-187.35M87.01M
Diluted EPS --2.93--4.15-5.20-5.002.30
R&D Expense 17.38M33.86M55.14M87.27M135.26M173.63M129.64M

Compounded Sales Growth

5 Years:-
1 Year:-99.80%

Compounded Profit Growth

5 Years:61.04%
1 Year:-

Stock Price Performance

1 Year:-20.49%
6 Months:-35.05%
3 Months:-20.72%
1 Month:+1.35%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -10.96M269.44M-306.78M370.02M615.89M338.02M
Current Assets ----285.77M347.29M588.89M315.43M
Cash & Equivalents -7.02M265.88M-279.05M331.15M559.93M287.42M
Inventory --------
Receivables ----0143.00K2.74M3.57M
Total Liabilities -10.46M7.72M-29.36M37.81M44.33M34.89M
Current Liabilities -4.49M7.18M-16.55M24.37M27.45M20.41M
Long Term Debt --------
Total Debt ----13.27M14.44M18.86M16.88M
Total Equity -7.18M-19.45M261.72M-277.42M332.21M571.55M303.13M
Shares Outstanding ----27.54M31.84M40.55M40.67M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -16.00M-36.89M--70.06M-124.51M-160.87M107.50M
Investing Cash Flow -271.00K-294.00K--1.24M-2.46M-1.93M-1.55M
Financing Cash Flow 14.00K296.04M-120.31M178.96M391.82M-378.47M
Capital Expenditure -271.00K-294.00K--1.24M-2.46M-1.93M-1.55M
Free Cash Flow -16.27M-37.19M--71.30M-126.97M-162.80M105.95M
Net Change in Cash ---49.01M51.98M229.02M-272.52M
Share Buybacks -----0375.00M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------
Operating Margin % -105.6%----110,954.3%-5,904.1%27.7%
Net Margin % -123.4%----101,319.2%-5,277.5%35.7%
ROE % 63.4%-17.3%--37.7%-46.1%-32.8%28.7%
ROCE % -163.3%-17.8%--37.1%-48.5%-35.6%21.3%

Shareholding Pattern

Insiders
3.65%
Institutions
96.04%
Public Float
99.67%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.19% 2.41M $27.13M
2 Nantahala Capital Management, LLC 6.87% 1.36M $15.30M
3 Vanguard Capital Management LLC 4.20% 831.42K $9.35M
4 Orbimed Advisors LLC. 3.84% 759.15K $8.54M
5 Qube Research & Technologies Ltd 3.66% 724.93K $8.16M
6 Jacobs Levy Equity Management, Inc. 3.57% 706.07K $7.94M
7 Federated Hermes, Inc. 3.48% 689.23K $7.75M
8 Vanguard Portfolio Management LLC 3.45% 682.04K $7.67M
9 Geode Capital Management, LLC 3.44% 681.46K $7.67M
10 Madison Avenue Partners, LP 3.17% 626.58K $7.05M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KROS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space